Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4(+) Diffuse Large B-Cell Lymphoma Cells

BACKGROUND AND PURPOSE: Around 40–50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL patients involve microtubule targeting agents (MTAs), however, their anticancer activity is limi...

Descripción completa

Detalles Bibliográficos
Autores principales: Falgàs, Aïda, Pallarès, Victor, Unzueta, Ugutz, Núñez, Yáiza, Sierra, Jorge, Gallardo, Alberto, Alba-Castellón, Lorena, Mangues, Maria Antonia, Álamo, Patricia, Villaverde, Antonio, Vázquez, Esther, Mangues, Ramon, Casanova, Isolda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944372/
https://www.ncbi.nlm.nih.gov/pubmed/33716502
http://dx.doi.org/10.2147/IJN.S289733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944372/
https://www.ncbi.nlm.nih.gov/pubmed/33716502
http://dx.doi.org/10.2147/IJN.S289733

Ejemplares similares